---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-001399"
form_type: "8-K"
ticker: "SNOA"
cik: "0001367083"
company_name: "Sonoma Pharmaceuticals, Inc."
filed_at: "2024-03-08T23:59:59+00:00"
generated_at: "2026-06-05T00:26:13.797485+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Sonoma Pharmaceuticals increases ATM offering capacity by $785,679

## Summary
- Amendment No. 1 to Dec 2023 Equity Distribution Agreement with Maxim Group LLC allows sale of up to $785,679 in additional common shares.
- Shares will be sold under existing effective S-3 registration statement (File No. 333-275311) and a prospectus supplement filed March 8, 2024.
- No specific use of proceeds disclosed; prior ATM offerings typically used for working capital and general corporate purposes.

## SEC filing metadata
- accession: 0001683168-24-001399
- form_type: 8-K
- ticker: SNOA
- cik: 0001367083
- company_name: Sonoma Pharmaceuticals, Inc.
- filed_at: 2024-03-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367083/000168316824001399/0001683168-24-001399-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367083/000168316824001399/sonoma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-001399
- JSON: https://secwatch.observer/filing/0001683168-24-001399.json
- Plain text: https://secwatch.observer/filing/0001683168-24-001399.txt

## Key facts
- Material Agreements
  Sonoma Pharmaceuticals, Inc. amended Amendment No. 1 with Maxim Group LLC valued at up to $785,679 (effective 2024-03-08).
  - Action: amendment
  - Agreement: atm program
  - Counterparty: Maxim Group LLC
  - Value: up to $785,679
  - Effective: 2024-03-08
  source text: On March 8, 2024, the Company entered into an amendment to the Agreement (“Amendment No. 1”) to provide for the sale of up to $785,679 of additional shares under the Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367083/000168316824001399/0001683168-24-001399-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.